Paper Details

  1. Home
  2. Paper Details

[FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].

Author: Abu FrehaNaim, Ben YakovGil, DizingofVitaly, EtzionOhad, FichAlexander, MonitinShulamit, MontanoDaniela, MushkaloAlex, ShwartsDoron, SikulerEmanuel, TakchickAnna, ZilbermanDorin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study retrospectively analyzes the experience of treating hepatitis C (HCV) genotype 1 patients with a triple regimen of pegylated interferon alfa, ribavirin, and a first-generation direct antiviral agent (DAA). The study highlights the significant progress in HCV treatment and the shift towards all-oral regimens with advanced DAAs.
Paper Details　
Original Abstract of the Article :
For the last decade the backbone of hepatitis C (HCV) treatment was the pan-genotyping dual therapy with pegylated interferon alfa in combination with Ribavirin. This regimen was limited in achieving sustained virological response (SVR) and accompanied by serious adverse events. In 2010 there was ov...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/27526553

データ提供：米国国立医学図書館（NLM）

A Revolution in Hepatitis C Treatment: Looking Back at the Rise of Triple Therapy

This study takes us on a journey through the evolution of hepatitis C treatment, highlighting the groundbreaking introduction of triple therapy. The authors reflect on the progress made over the past decade, from the limitations of dual therapy to the emergence of direct antiviral agents (DAAs), which have dramatically transformed the landscape of HCV treatment.

The Dawn of a New Era: Triple Therapy and its Impact on Hepatitis C Treatment

The study underscores the significant impact of triple therapy on hepatitis C treatment, showcasing the potential for achieving sustained virological response (SVR) with fewer adverse events. The introduction of DAAs targeting various viral proteins has paved the way for shorter, more effective treatment regimens with milder side effects.

Hope on the Horizon: The Future of HCV Treatment

The authors' experience with triple therapy serves as a testament to the remarkable progress made in the fight against HCV. It also fuels hope for the development of innovative treatment strategies for other viral diseases.

Dr.Camel's Conclusion

Imagine a desert where the sun relentlessly beats down, but a glimmer of hope emerges in the form of a new oasis—triple therapy. This research is a testament to the perseverance of scientists and clinicians in their quest to conquer hepatitis C, offering a beacon of hope for patients battling this challenging disease.

Date :
  1. Date Completed 2016-08-31
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27526553

DOI: Digital Object Identifier

27526553

Related Literature

Article Analysis
・Effects of boceprevir
SNS
PICO Info
in preparation
Languages

Hebrew

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.